Abstract
Immune checkpoint inhibition (ICI) has improved outcomes for pts with stage II-IV melanoma, although drug resistance and/or immune-related adverse events (irAEs) impact the majority of pts. Here we present a longitudinal analysis of immune cell subsets and correlation with pathological response and irAEs in pts on the neoadjuvant OpACIN-neo & PRADO trials (NCT02977052).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
